嗜中性白血球减少症治疗市场规模 - 依治疗类型、药物类型、给药途径、适应症、配销通路、全球预测，2024 年 - 2032 年

由于癌症、自体免疫疾病和传染病等通常与中性粒细胞减少症相关的疾病盛行率不断上升，预计中性粒细胞减少症治疗市场在2024 年至2032 年间将以超过4.1% 的复合年增长率增长。根据世界卫生组织的数据，2022 年，约有 2,000 万新诊断癌症病例和 970 万人死亡。随着这些潜在疾病的发生率在全球范围内不断上升，需要中性粒细胞减少症治疗的患者人数也相应增加。此外，医疗技术和药物开发的进步导致了新疗法和治疗方式的引入，以提高疗效和安全性。

由于与年龄相关的免疫系统变化以及慢性病患病率较高，老年人更容易患中性粒细胞减少症，因此对中性粒细胞减少症治疗的需求更大。此外，人们越来越认识到早期发现和管理中性粒细胞减少症的重要性，再加上获得医疗服务和诊断的机会的改善，将提高患者的诊断率和寻求治疗的行为。

中性粒细胞减少症治疗市场分为治疗类型、药物类型、给药途径、适应症、配销通路和区域。

有迹象表明，特发性中性粒细胞减少症领域的行业规模将在2024 年至2032 年期间以4% 的复合年增长率获得显着增长，其特点是中性粒细胞计数在没有明确原因的情况下减少。由于根本原因尚不清楚，人们越来越重视症状管理和支持性护理，以减轻感染风险并提高患者的生活品质。此外，医学研究的进步和对免疫系统的了解导致了标靶治疗和免疫调节剂的开发，这些药物在有效治疗特发性中性粒细胞减少症方面显示出希望。

根据药物类型，生物相似药领域的中性粒细胞减少症治疗市场预计在 2024 年和 2032 年复合年增长率为 4.8%，因为它们为原研生物药提供了具有成本效益的替代品。随着全球医疗保健系统寻求在不影响患者护理的情况下控製成本，生物相似药的可负担性和可用性正在推动其在中性粒细胞减少症治疗方案中的采用。此外，生物相似药经过严格的监管审查，以证明其与参考生物製剂具有可比性的功效和安全性，从而增强了医疗保健提供者和患者的信心。

由于人口迅速增长和传染病患者病率的增加，预计 2024 年至 2032 年亚太地区中性粒细胞减少症治疗行业规模将以 4.8% 的复合年增长率增长。中国和印度等国家医疗基础设施的改善和医疗支出的增加增加了中性粒细胞减少症诊断和治疗的机会。医疗保健专业人员和患者对中性粒细胞减少症的认识不断提高，加上医学研究和治疗方案的进步，将进一步刺激亚太地区的市场扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 中性粒细胞减少症盛行率增加
    • 化疗的使用不断增加
    • 旨在提高意识的政府措施和支持
    • 不断加强的研发力道扩大了强大的药物管道
    • 药物传输技术不断进步
    • 优惠的报销政策支持治疗的可及性
  • 产业陷阱与挑战
    • 严格的产品审核规定
    • 与治疗相关的不良反应
• 成长潜力分析
• 管道评估
• 报销场景
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按治疗类型，2018-2032 年

• 主要趋势
• 集落刺激因子 (CSF)
• 抗生素
• 抗霉菌药
• 抗病毒药
• 其他治疗类型

第 6 章：市场估计与预测：按药物类型，2018-2032

• 主要趋势
• 品牌化
• 生物相似药

第 7 章：市场估计与预测：按管理途径，2018-2032 年

• 主要趋势
• 口服
• 注射用

第 8 章：市场估计与预测：按指标划分，2018-2032 年

• 主要趋势
• 化疗引起的中性白血球减少症
• 週期性嗜中性白血球减少症
• 特发性嗜中性白血球减少症
• 先天性中性白血球减少症

第 9 章：市场估计与预测：按配销通路，2018-2032

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 10 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要动向：按地区
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 11 章：公司简介

• Amgen Inc.
• BeyondSpring Inc.
• Biocon Biologics Inc.
• Cellerant Therapeutics
• Coherus BioSciences, Inc.
• CuraTeQ Biologics Pvt. Ltd.
• Evive Biotech
• Kyowa Kirin Co., Ltd.
• Pfizer Inc.
• Sandoz Inc.
• Spectrum Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.

Neutropenia treatment market is anticipated to grow at over 4.1% CAGR between 2024 and 2032, driven by the increasing prevalence of conditions, such as cancer, autoimmune disorders, and infectious diseases, which are often associated with neutropenia. As per WHO, in 2022, there were approximately 20 million newly diagnosed cancer cases and 9.7 million fatalities. As the incidence of these underlying conditions is rising globally, there is a corresponding increase in the number of patients requiring neutropenia treatment. Additionally, advancements in medical technology and drug development have led to the introduction of novel therapies and treatment modalities for offering improved efficacy and safety profiles.

As older adults are more susceptible to neutropenia due to age-related changes in the immune system and the higher prevalence of chronic diseases, there is a greater demand for neutropenia treatment. Moreover, the increasing awareness about the importance of early detection and management of neutropenia coupled with improved access to healthcare services and diagnostics will drive the diagnosis rate and treatment-seeking behavior among patients.

The neutropenia treatment market is segmented into treatment type, drug type, route of administration, indication, distribution channel, and region.

By indication, the industry size from the idiopathic neutropenia segment will gain significant traction at 4% CAGR during 2024-2032, characterized by the decrease in neutrophil counts without an identifiable cause. As the underlying cause remains unclear, there is a growing emphasis on symptom management and supportive care to alleviate the risk of infections and improve the quality of life of patients. Additionally, advancements in medical research and understanding of the immune system have led to the development of targeted therapies and immunomodulatory agents that show promise in managing idiopathic neutropenia effectively.

Based on drug type, the neutropenia treatment market from the biosimilar drugs segment is anticipated to witness 4.8% CAGR throughout 2024 and 2032, as they offer cost-effective alternatives to originator biologic drugs. With healthcare systems worldwide seeking to contain costs without compromising patient care, the affordability and availability of biosimilar drugs is driving their adoption in neutropenia treatment regimens. Additionally, biosimilar drugs undergo rigorous regulatory scrutiny to demonstrate comparable efficacy and safety profiles to their reference biologics, instilling confidence among healthcare providers and patients.

Asia Pacific neutropenia treatment industry size is anticipated to grow at 4.8% CAGR over 2024-2032, attributed to the rapidly expanding population and increasing prevalence of infectious diseases. Improving healthcare infrastructure and rising healthcare expenditure in countries like China and India have enhanced the access to neutropenia diagnosis and treatment. The growing awareness about neutropenia among healthcare professionals and patients coupled with advancements in medical research and treatment options will further stimulate the market expansion in the Asia Pacific region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Forecast parameters
• 1.4 Data collection
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of neutropenia
    • 3.2.1.2 Growing utilization of chemotherapy
    • 3.2.1.3 Government initiatives and support aimed at raising awareness
    • 3.2.1.4 Rising R&D efforts expand robust drug pipeline
    • 3.2.1.5 Increasing advancements in pharmaceutical drug delivery technology
    • 3.2.1.6 Favorable reimbursement policies support treatment accessibility
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulations for product approvals
    • 3.2.2.2 Adverse effects associated with the treatment
• 3.3 Growth potential analysis
• 3.4 Pipeline assessment
• 3.5 Reimbursement scenario
• 3.6 Regulatory landscape
• 3.7 Porter's analysis
  • 3.7.1 Supplier power
  • 3.7.2 Buyer power
  • 3.7.3 Threat of new entrants
  • 3.7.4 Threat of substitutes
  • 3.7.5 Industry rivalry
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2018-2032 ($ Million)

• 5.1 Key trends
• 5.2 Colony-stimulating factors (CSFs)
• 5.3 Antibiotics
• 5.4 Antifungals
• 5.5 Antivirals
• 5.6 Other treatment types

Chapter 6 Market Estimates and Forecast, By Drug Type, 2018-2032 ($ Million)

• 6.1 Key trends
• 6.2 Branded
• 6.3 Biosimilars

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018-2032 ($ Million)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By Indication, 2018-2032 ($ Million)

• 8.1 Key trends
• 8.2 Chemotherapy-induced neutropenia
• 8.3 Cyclic neutropenia
• 8.4 Idiopathic neutropenia
• 8.5 Congenital neutropenia

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018-2032 ($ Million)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

• 10.1 Key trends, by region
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Amgen Inc.
• 11.2 BeyondSpring Inc.
• 11.3 Biocon Biologics Inc.
• 11.4 Cellerant Therapeutics
• 11.5 Coherus BioSciences, Inc.
• 11.6 CuraTeQ Biologics Pvt. Ltd.
• 11.7 Evive Biotech
• 11.8 Kyowa Kirin Co., Ltd.
• 11.9 Pfizer Inc.
• 11.10 Sandoz Inc.
• 11.11 Spectrum Pharmaceuticals
• 11.12 Teva Pharmaceutical Industries Ltd.